New Semisynthetic α-glucosidase Inhibitor from a Doubly-chemically Engineered Extract

Overview

Journal Nat Prod Bioprospect

Publisher Springer

Specialty Biology

Date 2025 Jan 4

PMID 39755857

Authors

Maria I Osella

Mario O Salazar

Carlos M Solis

Ricardo L E Furlan

Affiliations

Soon will be listed here.

Abstract

Chemically engineered extracts represent a promising source of new bioactive semi-synthetic molecules. Prepared through direct derivatization of natural extracts, they can include constituents enriched with elements and sub-structures that are less common in natural products compared to drugs. Fourteen such extracts were prepared through sequential reactions with hydrazine and a fluorinating reagent, and their α-glucosidase inhibition properties were compared. For the most bioactive mixture, a chemically modified propolis extract, enzyme inhibition increased 22 times due to the reaction sequence. Bio-guided fractionation led to the isolation of a new fluorinated pyrazole produced within the extract by chemical transformation of the flavonoid chrysin. The inhibitor results from the action of the two reagents used on four common functional groups present in natural products (carbonyl, phenol, aromatic carbon, and a double bond). The reactions led to the opening of a 6-member oxygenated heterocycle to produce a 5-member nitrogenated one, as well as the dehydroxylation and fluorination in two different positions of one of the aromatic rings of the natural starting material, all within a complex mixture of natural products. Overall, these transformations led to an approximately 20-fold increase in the α-glucosidase inhibition by the isolated inhibitor compared to its natural precursor.

References

Suzuki Y, Ichinohe K, Sugawara A, Kida S, Murase S, Zhang J . Development of Indole Alkaloid-Type Dual Immune Checkpoint Inhibitors Against CTLA-4 and PD-L1 Based on Diversity-Enhanced Extracts. Front Chem. 2021; 9:766107. PMC: 8630621. DOI: 10.3389/fchem.2021.766107. View

Righi D, Marcourt L, Koval A, Ducret V, Pellissier L, Mainetti A . Chemo-Diversification of Plant Extracts Using a Generic Bromination Reaction and Monitoring by Metabolite Profiling. ACS Comb Sci. 2019; 21(3):171-182. DOI: 10.1021/acscombsci.8b00132. View

Tomohara K, Maneenet J, Ohashi N, Nose T, Fujii R, Kim M . Ugi Adducts as Novel Anti-austerity Agents against PANC-1 Human Pancreatic Cancer Cell Line: A Rapid Synthetic Approach. Biol Pharm Bull. 2023; 46(10):1412-1420. DOI: 10.1248/bpb.b23-00224. View

Lescano L, Salazar M, Furlan R . Chemically engineered essential oils prepared through thiocyanation under solvent-free conditions: chemical and bioactivity alteration. Nat Prod Bioprospect. 2024; 14(1):35. PMC: 11143095. DOI: 10.1007/s13659-024-00456-w. View

Santos L, Fonseca M, Sokolonski A, Deegan K, Araujo R, Umsza-Guez M . Propolis: types, composition, biological activities, and veterinary product patent prospecting. J Sci Food Agric. 2019; 100(4):1369-1382. DOI: 10.1002/jsfa.10024. View

Daina A, Michielin O, Zoete V . SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017; 7:42717. PMC: 5335600. DOI: 10.1038/srep42717. View

Lipinski C, Lombardo F, Dominy B, Feeney P . Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46(1-3):3-26. DOI: 10.1016/s0169-409x(00)00129-0. View

Solis C, Salazar M, Ramallo I, Garcia P, Furlan R . A Tyrosinase Inhibitor from a Nitrogen-Enriched Chemically Engineered Extract. ACS Comb Sci. 2019; 21(9):622-627. DOI: 10.1021/acscombsci.9b00064. View

Maffei M, Gertsch J, Appendino G . Plant volatiles: production, function and pharmacology. Nat Prod Rep. 2011; 28(8):1359-80. DOI: 10.1039/c1np00021g. View

10.

Hu C, Jia W . Therapeutic medications against diabetes: What we have and what we expect. Adv Drug Deliv Rev. 2018; 139:3-15. DOI: 10.1016/j.addr.2018.11.008. View

11.

Salazar M, Ramallo I, Micheloni O, Sierra M, Furlan R . Chemically engineered extracts: bioactivity alteration through sulfonylation. Bioorg Med Chem Lett. 2009; 19(17):5067-70. DOI: 10.1016/j.bmcl.2009.07.038. View

12.

Zhang J, Xu W, Zhou Z, Li J, Jiang L, Zhang X . Antineoplastic Constituents from the Chemical Diversified Extract of Radix puerariae. Chem Biodivers. 2018; 16(1):e1800408. DOI: 10.1002/cbdv.201800408. View

13.

Nguyen D, Shaw L, Grant M . Inflammation in the pathogenesis of microvascular complications in diabetes. Front Endocrinol (Lausanne). 2012; 3:170. PMC: 3527746. DOI: 10.3389/fendo.2012.00170. View

14.

Lopez S, Ramallo I, Sierra M, Zacchino S, Furlan R . Chemically engineered extracts as an alternative source of bioactive natural product-like compounds. Proc Natl Acad Sci U S A. 2006; 104(2):441-4. PMC: 1766403. DOI: 10.1073/pnas.0608438104. View

15.

Baell J, Holloway G . New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 2010; 53(7):2719-40. DOI: 10.1021/jm901137j. View

16.

Zimmet P, Alberti K, Shaw J . Global and societal implications of the diabetes epidemic. Nature. 2001; 414(6865):782-7. DOI: 10.1038/414782a. View

17.

Salazar M, Micheloni O, Escalante A, Furlan R . Discovery of a β-glucosidase inhibitor from a chemically engineered extract prepared through sulfonylation. Mol Divers. 2011; 15(3):713-9. DOI: 10.1007/s11030-010-9301-2. View

18.

Veber D, Johnson S, Cheng H, Smith B, Ward K, Kopple K . Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002; 45(12):2615-23. DOI: 10.1021/jm020017n. View

19.

Li G, Lou H . Strategies to diversify natural products for drug discovery. Med Res Rev. 2017; 38(4):1255-1294. DOI: 10.1002/med.21474. View

20.

Cabezudo I, Salazar M, Ramallo I, Furlan R . Effect-directed analysis in food by thin-layer chromatography assays. Food Chem. 2022; 390:132937. DOI: 10.1016/j.foodchem.2022.132937. View